{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:26:34Z","timestamp":1792661194895,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.vaccine.2011.02.008","type":"journal-article","created":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T09:13:12Z","timestamp":1298365992000},"page":"2881-2886","source":"Crossref","is-referenced-by-count":1,"title":["Modelling borderline and mild dysplasia associated with HPV 6 and 11 infection"],"prefix":"10.1016","volume":"29","author":[{"given":"Ruth","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Soldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.02.008_bib0005","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0010","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl. 12","key":"10.1016\/j.vaccine.2011.02.008_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1258\/0956462011924100","article-title":"European guideline for the management of anogenital warts","volume":"3","author":"von Krogh","year":"2001","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0020","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1086\/342109","article-title":"External genital warts: diagnosis, treatment, and prevention","volume":"35","author":"Wiley","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0025","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0030","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0035","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1086\/428850","article-title":"Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica","volume":"191","author":"Herrero","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0040","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/01.pas.0000213291.96401.48","article-title":"The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN)","volume":"30","author":"Srodon","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0045","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0050","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.bjc.6605747","article-title":"Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England","volume":"103","author":"Howell-Jones","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0060","unstructured":"Department of Health. Cervical screening programme, England 2008\u201309, 2010."},{"key":"10.1016\/j.vaccine.2011.02.008_bib0065","unstructured":"NHS Cancer Screening Programme. NHSCSP Publication No. 20. Colposcopy and programme management: guidelines for the NHS cervical screening programme, http:\/\/www.cancerscreening.nhs.uk\/cervical\/publications\/nhscsp20.pdf; 2004."},{"key":"10.1016\/j.vaccine.2011.02.008_bib0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/0272989X09336140","article-title":"Estimating progression rates for human papillomavirus infection from epidemiological data","volume":"30","author":"Jit","year":"2010","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0075","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1471-0528.2007.01261.x","article-title":"Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales","volume":"114","author":"Martin-Hirsch","year":"2007","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0080","series-title":"Unit costs of health and social care 2007","author":"Curtis","year":"2007"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1185\/030079906X99972","article-title":"Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK","volume":"22","author":"Brown","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8200","article-title":"Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis","volume":"8","author":"Karnon","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0095","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0100","unstructured":"Parliamentary Office of Science and Technology. Postnote: cervical cancer (number 316), http:\/\/www.parliament.uk\/documents\/post\/postpn316.pdf; 2011 [accessed 27.1.11]."},{"key":"10.1016\/j.vaccine.2011.02.008_bib0105","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/aje\/kwk059","article-title":"Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty","volume":"165","author":"Van de Velde","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0110","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/sj.bjc.6604972","article-title":"Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women","volume":"100","author":"Mu\u00f1oz","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0125","doi-asserted-by":"crossref","unstructured":"Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiology. Biomarkers & Prevention: a publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2010;19:1585\u201394.","DOI":"10.1158\/1055-9965.EPI-09-1235"},{"key":"10.1016\/j.vaccine.2011.02.008_bib0120","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1086\/587698","article-title":"Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination","volume":"197","author":"Trottier","year":"2008","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1100209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1100209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T18:57:33Z","timestamp":1560020253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1100209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":24,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0264410X1100209X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.02.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}